{"id":"placebo-to-telcagepant-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL236593","moleculeType":"Small molecule","molecularWeight":"566.53"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by blocking the action of calcitonin gene-related peptide (CGRP), a molecule involved in the transmission of pain signals. This leads to a reduction in migraine frequency and severity. By inhibiting CGRP, telcagepant helps to alleviate migraine symptoms.","oneSentence":"Telcagepant is a calcitonin gene-related peptide receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:52.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute treatment of migraine attacks with or without aura"}]},"trialDetails":[{"nctId":"NCT01125774","phase":"PHASE2, PHASE3","title":"Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-01","conditions":"Migraine","enrollment":4548},{"nctId":"NCT00758836","phase":"PHASE2","title":"A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-03","conditions":"Migraine","enrollment":683},{"nctId":"NCT00662818","phase":"PHASE3","title":"Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03-17","conditions":"Migraine Disorders, Heart Disease, Cerebrovascular Accident","enrollment":165},{"nctId":"NCT01294709","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02-12","conditions":"Angina Pectoris, Coronary Heart Disease, Calcitonin Gene-related Peptide Receptor","enrollment":64},{"nctId":"NCT00483704","phase":"PHASE3","title":"Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08-14","conditions":"Migraines","enrollment":1935},{"nctId":"NCT00797667","phase":"PHASE2","title":"MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-11-12","conditions":"Migraine","enrollment":660},{"nctId":"NCT00442936","phase":"PHASE3","title":"Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-15","conditions":"Migraine","enrollment":1380},{"nctId":"NCT00443209","phase":"PHASE3","title":"Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-21","conditions":"Migraine","enrollment":1068}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to telcagepant tablets","genericName":"Placebo to telcagepant tablets","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Telcagepant is a calcitonin gene-related peptide receptor antagonist. Used for Acute treatment of migraine attacks with or without aura.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}